Download presentation
Presentation is loading. Please wait.
1
Volume 131, Issue 1, Pages 59-68 (July 2006)
Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy Chee–Kin Hui, Winnie W.W. Cheung, Hai–Ying Zhang, Wing–Yan Au, Yui–Hung Yueng, Anskar Y.H. Leung, Nancy Leung, John M. Luk, Albert K.W. Lie, Yok–Lam Kwong, Raymond Liang, George K.K. Lau Gastroenterology Volume 131, Issue 1, Pages (July 2006) DOI: /j.gastro Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions
2
Figure 1 Serial serum alanine aminotransaminase, HBV DNA, and HBV serology of 2 patients (patient 6 and patient 7) who developed de novo HBV-related hepatitis. Arrow, Time lamivudine was commenced. (B) R+CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone; (A) R+FND, rituximab, fludarabine, mitoxantrone, dexamethasone; LOD, limit of detection. Gastroenterology , 59-68DOI: ( /j.gastro ) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions
3
Figure 2 Cumulative probability of developing de novo HBV-related hepatitis after chemotherapy in relation to (A) rituximab plus steroid-containing regimen and (B) rituximab-containing regimen. Gastroenterology , 59-68DOI: ( /j.gastro ) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions
4
Figure 3 Cumulative probability of fulminant hepatic failure in relation to (A) de novo hepatitis B virus related hepatitis and (B) hepatitis B core antibody. Gastroenterology , 59-68DOI: ( /j.gastro ) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.